Atom Investors LP Invests $1.57 Million in Haemonetics Co. (NYSE:HAE)

Atom Investors LP acquired a new position in Haemonetics Co. (NYSE:HAE) during the third quarter, Holdings Channel reports. The firm acquired 19,545 shares of the medical instruments supplier’s stock, valued at approximately $1,571,000.

Other large investors also recently added to or reduced their stakes in the company. Quarry LP purchased a new stake in shares of Haemonetics in the 2nd quarter valued at about $39,000. Daiwa Securities Group Inc. bought a new position in shares of Haemonetics in the second quarter worth approximately $82,000. Canada Pension Plan Investment Board purchased a new stake in Haemonetics in the second quarter valued at approximately $83,000. Nisa Investment Advisors LLC lifted its position in Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 632 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Haemonetics in the 2nd quarter worth approximately $140,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Up 0.0 %

Shares of HAE opened at $87.48 on Tuesday. Haemonetics Co. has a 1-year low of $70.25 and a 1-year high of $97.97. The firm has a market capitalization of $4.39 billion, a price-to-earnings ratio of 36.30, a PEG ratio of 1.36 and a beta of 0.32. The firm’s 50-day moving average price is $80.21 and its 200-day moving average price is $82.00. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. The firm had revenue of $345.50 million for the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.99 EPS. Sell-side analysts anticipate that Haemonetics Co. will post 4.59 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $112.00 price objective on shares of Haemonetics in a research report on Friday, November 15th. Citigroup lowered their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. Raymond James upgraded Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective for the company in a report on Friday, November 8th. Barrington Research reissued an “outperform” rating and set a $108.00 price objective on shares of Haemonetics in a report on Friday, November 8th. Finally, Bank of America began coverage on Haemonetics in a research report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 target price for the company. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $107.88.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.